Author: Dr Kevin Auton, Managing Director
Aseptika’s latest innovation is the BuddyWOTCH™, a unique product in that it will be the first wearable which accurately measures levels of blood oxygenation and heart rate while the wearer is moving and can be worn continuously for life. The BuddyWOTCH integrates several vital sign monitoring devices, whilst being medically-certified wearable, W-O-T-C-H stands for (Walking, Oxygen SpO2, Temperature, Camera, and Heart rate) into a smartwatch format as cross-over medical device with consumer functionality.
Our goals for the BuddyWOTCH are:
- To be worn 99.5% of the day, to provide early warning of respiratory failure. This means a highly innovative way to charge the battery powered devices;
- New index of respiratory efficiency (Respiratory Exercise Tolerance Index) to replace laboratory-based tests (“6-minute walk” and “sit-to-stand”) to predict life expectancy. Here the key innovation is to measure blood oxygen desaturation while the wearer is moving to determine tolerance to exercise (respiratory efficiency). Movement artefacts in traditional pulse oximeters cause signal loss when the subject moves. Our FingerBand SpO2 removes these, miniaturises and allows a constant read-out day and night. Measurement at the wrist is impractically complex (which is why most non-medical smartwatches only measure heart rate – and not very accurately)
- Operates with a medically-certifiable OS, while at the same time, allowing the user to run smartwatch Apps; and
- Securely transmit data to and from the BuddyWOTCH without the need for Smartphone or Tablets. BuddyWOTCH therefore has: Bluetooth, WiFi and cellular communications so as to be Always Connected.
Supporting patients to manage long-term conditions more effectively is a high priority for the NHS and Activ8rlives. The aim is for patients to become empowered experts in their own health and safely manage their condition in the comfort of their own home, with fewer unplanned hospital admissions and a higher overall quality of life.
All our innovations are developed in conjunction with input from both patients and clinical staff. Patients find the Activ8rlives self-monitoring tools, Apps and website easy to use and this has led to adherence rates of over 90% and up to 99% in some of our clinical trials. Participants have described how self-monitoring has given them greater insight into their health and helped them to make positive changes in their lives. One individual with bronchiectasis achieved a 20% improvement in lung function and was no longer classed as being at high risk of hospitalisation.
Aseptika received investment to date of £920,000 from SBRI Healthcare Phases 1 and 2 contracts to support the development of the BuddyWOTCH, which will provide continuous data collection to help people with respiratory disease and other long-term health conditions to better manage their condition at home.
Aseptika is seeking further funding to complete the development, production, clinical trials and certification for the BuddyWOTCH. A patent application was made to protect Aseptika’s inventions for the BuddyWOTCH worldwide.Posted in: industry ,